Provided by Tiger Trade Technology Pte. Ltd.

Novavax

9.30
-0.5500-5.58%
Post-market: 9.20-0.1000-1.08%17:43 EDT
Volume:5.89M
Turnover:54.50M
Market Cap:1.53B
PE:-6.13
High:9.68
Open:9.64
Low:9.11
Close:9.85
52wk High:11.97
52wk Low:6.20
Shares:164.43M
Float Shares:143.00M
Volume Ratio:1.15
T/O Rate:4.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5181
EPS(LYR):2.58
ROE:-898.20%
ROA:-6.51%
PB:-8.02
PE(LYR):3.60

Loading ...

U.S.-Listed Shares of BioNTech up 17%, Novavax Rise 4.5% After Moderna and Merck's Skin Cancer Vaccine Succeeds in Late-Stage Trial

THOMSON REUTERS
·
Aug 19

U.S.-Listed Shares of BioNTech up 17.4%, Novavax Rises 5.9%

THOMSON REUTERS
·
Aug 19

Novavax Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Aug 19

What Is Drawing Fresh Attention To Novavax (NVAX)?

Simply Wall St.
·
Aug 17

Novavax Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 14

Novavax (NVDA) Could Be 42% Undervalued Following Losses And Shelf Registration

Simply Wall St.
·
Aug 10

Novavax Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 08

Novavax, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Novavax Exec Says Plans to Pay Off Pandemic Era Epa Liabilities by Q1 of 2029 - Conf Call

THOMSON REUTERS
·
Aug 06

Novavax Shares up 1.6% Premarket After Co Lifts 2026 Revenue Forecast

THOMSON REUTERS
·
Aug 06

Novavax Q2 2026 earnings: Revenue falls as prior-year payments roll off

TradingKey
·
Aug 06

Earnings Flash (NVAX) Novavax Posts Q2 Net Loss of $0.32 a Share, vs. FactSet Est. of $0.38 Loss

MT Newswires Live
·
Aug 06

Novavax Outlook FY Adjusted Total Revenue USD 235-275 Million

THOMSON REUTERS
·
Aug 06

Novavax Q2 EPS $-0.32 Ibes Estimate $-0.39

THOMSON REUTERS
·
Aug 06

Novavax Outlook 2026 Adj Revenue $235 Mln to $275 Mln vs Ibes Estimate $389.2 Mln

THOMSON REUTERS
·
Aug 06

Novavax: on Track to Advance C. Difficile Vaccine Program into the Clinic as Early as 2027

THOMSON REUTERS
·
Aug 06

Novavax: Manufacturing Technology Transfer to Sanofi for Nuvaxovid Expected to be Completed Mid-2027. Would Trigger $75 Mln Milestone Payment to Co

THOMSON REUTERS
·
Aug 06

Novavax Q2 REV $57 Mln vs Ibes Estimate $52.5 Mln

THOMSON REUTERS
·
Aug 06

Novavax Lifts Annual Revenue Forecast as Licensing Bets Offset Weak Vaccine Demand

Reuters
·
Aug 06

Novavax Outlook 2026 Adj Combined R&D and SG&a Expenses $310 Mln to $340 Mln

THOMSON REUTERS
·
Aug 06